Development of a mHealth Intervention for Ambivalent Smokers

Sponsor
Kaiser Permanente (Other)
Overall Status
Completed
CT.gov ID
NCT04560868
Collaborator
National Cancer Institute (NCI) (NIH)
57
1
2
9.3
6.1

Study Details

Study Description

Brief Summary

The current pilot study will assess the feasibility and acceptability of a novel mHealth app designed for people who are ambivalent about quitting smoking. Results will be used to refine the intervention and plan for a future randomized effectiveness trial.

Condition or Disease Intervention/Treatment Phase
  • Device: Control mHealth program
  • Device: Experimental mHealth program
  • Drug: Nicotine patch
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
57 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Device Feasibility
Official Title:
Development of a mHealth Intervention for Ambivalent Smokers
Actual Study Start Date :
Dec 17, 2020
Actual Primary Completion Date :
Sep 27, 2021
Actual Study Completion Date :
Sep 27, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control

Device: Control mHealth program
The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.

Drug: Nicotine patch
Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.

Experimental: Experimental

Device: Experimental mHealth program
The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.

Drug: Nicotine patch
Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.

Outcome Measures

Primary Outcome Measures

  1. Smoking Cessation [Assessed at 3-month follow-up]

    7-day point prevalent abstinence

  2. Quit Attempt [Assessed at 3-month follow-up]

    Intentional smoking quit attempt lasting at least 24 hours

  3. Program Engagement [Assessed at 3-month follow-up]

    Number of unique app user-sessions

Secondary Outcome Measures

  1. Smoking Cessation [Assessed at 1-month follow-up]

    7-day point prevalent abstinence

  2. Smoking Reduction [Assessed at 1 and 3-month follow-up]

    Reduction in number of cigarettes smoked per day

  3. Self-efficacy [Assessed at 1 and 3-month follow-up]

    Self-reported confidence can quit or stay quit

  4. Helpfulness of assigned app [Assessed at 1 and 3-month follow-up]

    Overall rating of helpfulness based on mean rating across program features

  5. Satisfaction of assigned app [Assessed at 1 and 3-month follow-up]

    Overall rating of satisfaction based on mean rating across program features

  6. Program Engagement - Earned badges [Assessed at 1 and 3-month follow-up]

    Average number of accumulated badge rewards

  7. Nicotine Replacement Therapy [Assessed at 1 and 3-month follow-up]

    Number of participants by arm who requested free nicotine patches

  8. Quit Attempt [Assessed at 1 month follow-up]

    Intentional smoking quit attempt lasting at least 24 hours

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years or older;

  • Can speak/read English;

  • Current smoker;

  • Own and regularly use an eligible smartphone;

  • No vision impairments;

  • Willing to install and use the study program;

  • Willing to use birth control if elect to use nicotine replacement during the study (females);

  • Meet definition for ambivalence

  • Not actively using treatment

Exclusion Criteria:
  • Smoke less than 10 cigarettes per day

  • Self-report a lifetime history of dementia, manic depression, bipolar disorder, or schizophrenia;

  • Have medical contraindications for nicotine replacement therapy;

  • Another household member is enrolled in the study

  • Unable to verify contact information

  • Fail to install app

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kaiser Permanente Washington Health Research Institute Seattle Washington United States 98101

Sponsors and Collaborators

  • Kaiser Permanente
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Jennifer McClure, PhD, Kaiser Permanente

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kaiser Permanente
ClinicalTrials.gov Identifier:
NCT04560868
Other Study ID Numbers:
  • 1401452
  • R21CA234003
First Posted:
Sep 23, 2020
Last Update Posted:
Nov 10, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kaiser Permanente
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 10, 2021